Sign in

NCT05108090Recruiting

Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck

Source: ClinicalTrials.gov · Last updated 11 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

The purpose of this study is to research if a type of biopsy known as sentinel lymph node biopsy (SLNB) can help in determining the rate of tumor deposits that are hard to detect and identify in node-negative cutaneous squamous cell carcinoma of the head or neck.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
94 (estimated)
First submitted
10 Oct 2021
Start date
25 Oct 2021
Primary completion date
Sept 2026
Lead sponsor
Indiana University
NCT number
NCT05108090

What you commit to

  • Study type: Interventional
  • Planned participants: 94
  • From 25 Oct 2021 to the primary completion date, Sept 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Patient unable to receive and/or allergic to 99m-Technetium sulfur colloid

Other

  • Clinical evidence of satellite lesions, in-transit, regional nodal or distant metastases
  • Known biopsy proven synchronous primary cutaneous squamous cell carcinoma
  • Pregnant patients
  • Patients unable to undergo general anesthesia
  • Patient unable to receive contrasted imaging studies

Who the study is looking for

  • Patients ≥ 18 years old at the time of informed consent
  • Ability to provide written informed consent and HIPAA authorization
  • Primary or recurrent invasive cutaneous squamous cell carcinoma of the head or neck, clinically staged T2-T4 based on AJCC staging
  • Clinically and radiographically regional node-negative (no evidence of regional lymph node metastasis or distant metastasis)
  • Able to undergo general anesthesia for sentinel lymph node biopsy
  • Able to undergo CT scan with contrast or MRI with contrast
  • Undergo surgical resection (Moh's or micrographic resection or standard excision with sentinel lymph node biopsy) within 8 weeks of imaging

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Indiana University Melvin & Bren Simon Cancer Center
Coordinator of this site? Confirm its status
IndianapolisUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.